Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045828 | 0.86 | GPR84 (0.61) | GPR84HTR2ACA2PTPN5KDM4E | |
| SCHEMBL20548794 | 0.86 | GPR84 (0.71) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL5881100 | 0.85 | GPR84 (1.00) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL9889542 | 0.84 | HTR2A (0.71) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL1094688 | 0.83 | GPR84 (0.74) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL3083899 | 0.82 | GPR84 (0.71) | GPR84HTR2ACA2PTPN5KDM4E | |
| SCHEMBL14159329 | 0.82 | GPR84 (0.71) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL7004405 | 0.82 | HTR2A (0.73) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL5212531 | 0.82 | HTR2A (0.73) | GPR84HTR2ACA2KDM4EKEAP1 | |
| SCHEMBL29585828 | 0.82 | HTR2A (0.73) | GPR84HTR2ACA2KDM4EKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103709171-B | There is the pyridazine also derivative of [3,4-b] indole framework structure and synthetic method thereof | WUHAN UNIVERSITY (CN) | 2015-09-16 | — | — | CN | claimed |
| EP-0181152-B1 | PIPERAZINE COMPOUND AS PAF-ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-13 | — | — | EP | claimed |
| EP-0243122-A2 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| EP-0181152-A1 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | claimed |
| JP-62265284-A | — | — | None | — | — | JP | disclosed |
| WO-2024089049-A1 | MODULATORS OF SORTILIN ACTIVITY | INSUSENSE ApS (DK) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230250364-A1 | LAUNDRY CARE COMPOSITIONS, METHODS, AND TEST KITS FOR DETERMINING AUTHENTICITY | PROCTER & GAMBLE (US) | 2023-08-10 | — | — | US | disclosed |
| CN-1871188-A | Method for producing aromatic unsaturated compound | SUMITOMO CHEMICAL CO (JP) | 2006-11-29 | — | — | CN | disclosed |
| EP-1666440-A1 | METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0384349-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
| EP-0328026-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-16 | — | — | EP | disclosed |
| EP-0243122-A3 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-13 | — | — | EP | disclosed |
| JP-S62265284-A | PIPERAZINE COMPOUND | FUJISAWA PHARMACEUT CO LTD | 1987-11-18 | — | — | JP | disclosed |
| EP-0243122-A2 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | disclosed |
| US-3878213-A | CERTAIN 4-(N-PYRIMIDIN-2-YLSULFAMOYL)-PHENYLACETAMIDES | AHRENS HANNS | 1975-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | GPR84 736/4885HTR2A 74/4885CA2 1310/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | GPR84 3447/4885HTR2A 4347/4885CA2 1305/4885 |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | GPR84 3600/4885HTR2A 3770/4885CA2 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.